C4 Therapeutics, Inc. CCCC
Key Stats
- Today's Range
- $3.58 – $3.72
- 50-Day Range
- $3.36 – $5.17
- 52-Week Range
- $1.44 – $5.17
- Volume
- 1.82 million shs
- Average Volume
- 3.70 million shs
- Market Cap
- $402.46 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.72
- Price / Sales
- 11.54
Short Interest
- Short Interest
- 0.32%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $34.86 million
- Net Income
- $-103,801,000
- Net Margin
- -297.76%
- Return on Equity
- -44.31%
- Debt-to-Equity
- —
About C4 Therapeutics, Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Related Stocks
Compare head-to-head: CCCC vs AMGN·CCCC vs HALO·CCCC vs RGEN·CCCC vs IMVT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.